Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
News|Slideshows|August 28, 2023
IJMSC Online First: August 2023
Author(s)Erin E Gyomber
Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.
Advertisement
The International Journal of MS Care is a peer-reviewed, multidisciplinary, open access journal and the official journal of
Click through the slides below to preview the latest research published Online First in IJMSC. Click any slide to read the full research article.
—————————————————
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease
2
CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease
3
Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches
4
FDA Action Update, September 2026: Approvals, Clearances, and Priority Review
5